The emergence of new forms of serums forces us to reconsider the approach to the issue of using antibacterial drugs of the penicillin group. The most ancient and already well-tested antibiotics have been in service with doctors for a long time and, ultimately, may be surpassed by new generation antibiotics that quickly adapt to beta-lactamase deficiency. Proponents of these new antibiotics argue that their consistent use in cases of illness caused by a group of penicillin-resistant microbes increases the patient's chances of survival. Ultimately, we can say that only clinical trials will allow the current debate about a more effective way to treat a patient with pneumonia.